Abstract
Aims
To describe the utilization of antiasthmatic drugs in Sweden and to explore regional variations in drug utilization and adherence to guidelines for rational drug prescribing of antiasthmatics and their rationale.
Methods
Data on antiasthmatic drugs dispensed between July 2005 and December 2008 to all Swedish citizens aged between 18 and 44 years were obtained from the Swedish National Prescribed Drug Register. The period prevalence was determined by analyzing the number of users/1000 inhabitants, and the incidence by analyzing the number of new users after an 18-month drug-free wash-out period. Three drug-related indicators were used to assess the adherence to guidelines. All measures were analyzed by gender and region.
Results
A total of 161,000 patients were dispensed antiasthmatics in 2007, corresponding to a prevalence of 4 and 6% among men and women, respectively; the incidence rates were 2 and 3%, respectively. The total drug utilization and adherence to guidelines varied between regions. The total drug expenditures of antiastmatics were 258 million SEK (28 million euro), with fixed dose combinations accounting for 46% of the expenditure. No relation was found between models for allocating prescribing budgets or clear Drug and Therapeutics Committee recommendations and adherence to guidelines.
Conclusion
There are large regional variations in the utilization of antiasthmatics between Swedish regions, with substantial room for improvement in the adherence to guidelines. New methods of influencing physician behavior may be needed in the future to enhance adherence.
Similar content being viewed by others
Abbreviations
- R03:
-
Respiratory system
- R03A:
-
Adrenergics inhalants
- R03AC:
-
Selective beta-2-adrenoreceptor agonists
- R03AK:
-
Adrenergics and other drugs for obstructive airway diseases, combinations
- R03BA:
-
Glucocorticoids
- LABA:
-
Long-acting beta-2-adrenoceptor agonist
- SABA:
-
Short-acting beta-2-agonists
References
Burney PG, Luczynska C, Chinn S, Jarvis D (1994) The European community respiratory health survey. Eur Respir J 7(5):954–960
Läkemedelsverket Medical Products Agency (2007) Farmakologisk behandling vid astma–2007. Tryckt version. 2007(18) Temanummer
Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lenfant C, O'Byrne P et al (2007) GINA guidelines on asthma and beyond. Allergy 62(2):102–112
Henriksson F, Hjortsberg C, Rehnberg C (1999) Pharmaceutical expenditure in Sweden. Health Policy 47(2):125–144
Moise P, Docteur E (2007) OECD Health Working Papers No. 28. Pharmaceutical pricing and reimbursement in Sweden:13 September 2007. Available at: htttp://www.olis.oecd.org/olis/2007doc.nsf/FREDATCORPLOOK/NT00002E52/$ FILE/JTO3231887.PDF (assessed 2 Feb 2008)
Socialstyrelsen (2008) Läkemedelsförsäljningen I Sverige—analys och prognos. Stockholm
Socialstyrelsen (2007) Läkemedelsförsäljningen I Sverige—analys och prognos (September 2007). Stockholm
Brodin H (1987) Regional variations in pharmaceutical consumption in Sweden. Linköping University, Linköping
Gerdtham UG, Hertzman P, Jonsson B, Boman G (1996) Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden 1978 to 1991. Med Care 34(12):1188–1198
Haupt D, Krigsman K, Nilsson JL (2008) Medication persistence among patients with asthma/COPD drugs. Pharm World Sci 30(5):509–514
Krigsman K, Moen J, Nilsson JL, Ring L (2007) Refill adherence by the elderly for asthma/chronic obstructive pulmonary disease drugs dispensed over a 10-year period. J Clin Pharm Ther 32(6):603–611
Eckerlund I, Gerdtham UG (1998) Econometric analysis of variation in cesarean section rates. A cross-sectional study of 59 obstetrical departments in Sweden. Int J Technol Assess Health Care 14(4):774–787
Gillissen A (2007) Patients' adherence in asthma. J Physiol Pharmacol 58[Suppl 5]:205–222
Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njolstad I et al (2007) Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption—an individual-level prescription database study. BMC Clin Pharmacol 7:14
Wettermark B, Hammar N, MichaelFored C, Leimanis A, Otterblad Olausson P, Bergman U et al (2007) The new Swedish prescribed drug register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726–735
Arnlind MH, Nokela M, Rehnberg C, Jonsson EW (2006) The relationship between pharmaceutical costs, disease severity, and health-related quality of life in asthmatics in Swedish primary care. J Asthma 43(8):585–591
Sjöqvist F, Bergman U, Dahl ML (2002) eaDatcaSeWDI. Drug and therapeutics committees: a Swedish experience. WHO Drug Inf 16:207–213
Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V (2008) Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 26(7):537–550
Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL (2009) Swedish experience in ambulatory care with multifaceted national and regional drug reforms and initiatives: global relevance. Expert Review. Pharmacoeconomics Outcomes Res 9(1):65–83
Anell A (2005) Swedish healthcare under pressure. Health Econ 14[Suppl 1]:S237–S254
Socialdepartementet (2005) Socialdepartementet förordning (2005:363) om läkemedelsregister hos Socialstyrelsen. Stockholm
World Health Organization (2005) Guidelines for ATC classification an DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology. Available at: www.whocc.no. WHO, Oslo
World Health Organization (2007) Guidelines for ATC classification and DDD assignment. WHO Collaborationg Center for Drug Statistics Methodology 2007: Available at: http://www.whocc.no/
World Health Organization (2003) Introduction to drug utilisation research, NLM classification WB 330. WHO, Oslo
Hallas J, Stovring H (2006) Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol 98(3):260–265
Bergstrom G, Karlberg I (2007) Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective. Health Policy 81(2-3):358–367
Jansson S, Anell A (2006) The impact of decentralised drug-budgets in Sweden—a survey of physicians' attitudes towards costs and cost-effectiveness. Health Policy 76(3):299–311
Haaijer-Ruskamp F, HHoven J, Mol P (2004) A conceptual framework for constructing prescribing quality indicators: a poroposal. DURQUIM: Drug Utilization Quality Indicator Meeting. WHO, Mechelen
Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH (2005) Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13–15 May 2004). Eur J Clin Pharmacol 60(11):831–834
Socialstyrelsen (2003) Indikatorer för utvärdering av kvaliteten I äldres läkemedelsterapi—socialstyrelsens förslag. Stockholm
Naturhistoriska riksmuseet (2007) Årets pollensäsong—nu börjar det! Available at: htwww.nrm.se/sv/menss/pressmeddelandessmeddelanden/200t spollensasongnuborjardet.1374.html
Ehrs PO, Nokela M, Stallberg B, Hjemdahl P, Wikstrom Jonsson E (2006) Brief questionnaires for patient-reported outcomes in asthma: validation and usefulness in a primary care setting. Chest 129(4):925–932
Kamble S, Bharmal M (2009) Incremental direct expenditure of treating asthma in the United States. J Asthma 46(1):73–80
Läkemedelsverket (2002) Bakgrukumentation—akologisk ndling av astma (database on the Internet). Available at: http://www.lakemedelsverket.se/upload/Hälso-%20och%20sjukvård/behandlingsrek/bakg_dok/astma_bakgrund.pdf
Osborne ML, Vollmer WM, Linton KL, Buist AS (1998) Characteristics of patients with asthma within a large HMO: a comparison by age and gender. Am J Respir Crit Care Med 157(1):123–128
Weiner P, Magadle R, Massarwa F, Beckerman M, Berar-Yanay N (2002) Influence of gender and inspiratory muscle training on the perception of dyspnea in patients with asthma. Chest 122(1):197–201
Abraham B, Antó JM, Barreiro E, Bel EHD, Bousquet J, Castellsagud J, et al (2003) The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 22(3):470–477
Diette GB, Wu AW, Skinner EA, Markson L, Clark RD, McDonald RC et al (1999) Treatment patterns among adult patients with asthma: factors associated with overuse of inhaled beta-agonists and underuse of inhaled corticosteroids. Arch Intern Med 159(22):2697–2704
Cockcroft DW, Davis BE (2006) Airway hyperresponsiveness as a determinant of the early asthmatic response to inhaled allergen. J Asthma 43(3):175–178
Hasselgren M, Arne M, Lindahl A, Janson S, Lundback B (2001) Estimated prevalences of respiratory symptoms, asthma and chronic obstructive pulmonary disease related to detection rate in primary health care. Scand J Prim Health Care 19(1):54–57
Nilsson JLG, Haupt D, Krigsman K, Moen J (2009) Asthma/COPD drugs reflecting disease prevalence, patient adherence and persistence. Expert Review (serial on the Internet)
Beasley R, Martinez FD, Hackshaw A, Rabe KF, Sterk PJ, Djukanovic R (2009) Safety of long-acting beta-agonists: urgent need to clear the air remains. Eur Respir J 33(1):3–5
Cates CJ, Cates MJ, Lasserson TJ (2008) Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 4:CD006923
GINA Guidelines. (2008) Pocket guide for asthma management and prevention 2008: Available at: http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=1562
Ni CM, Greenstone IR, Ducharme FM (2005) Addition of inhaled long-acting beta2- agonists to inhaled steroids as first line therapy for persistent asthma in steroid- naive adults. Cochrane Database Syst Rev 2:CD005307
Partridge MR, Fabbri LM, Chung KF (2000) Delivering effective asthma care—how do we implement asthma guidelines? Eur Respir J 15(2):235–237
Wiener-Ogilvie S, Huby G, Pinnock H, Gillies J, Sheikh A (2008) Practice organisational characteristics can impact on compliance with the BTS/SIGN asthma guideline: qualitative comparative case study in primary care. BMC Fam Pract 9:32
Eccles MP, Soutter J, Bateman DN, Campbell M, Smith JM (1996) Influences on prescribing in non-fundholding general practices. Br J Gen Pract 46(406):287–290
Mansouri M, Lockyer J (2007) A meta-analysis of continuing medical education effectiveness. J Contin Educ Health Prof 27(1):6–15
Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA (1998) Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. Br Med J 317(7156):465–468
Taylor DM, Auble TE, Calhoun WJ, Mosesso VN Jr (1999) Current outpatient management of asthma shows poor compliance with International Consensus Guidelines. Chest 116(6):1638–1645
Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L et al (2004) Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 8(6):1–72
Brown MM, Brown GC, Sharma S, Hollands H, Smith AF (2001) Physician manpower and health care expenditures in the United States: a thirty-year perspective. J Health Care Finance 27(4):55–64
Folland S, Goodman A, Stano M (eds) (2004) The ecoonomics of health and health care. Pearson Prentice Hall, Upper Saddle River
Leonard C, Stordeur S, Roberfroid D (2009) Association between physician density and health care consumption: A systematic review of the evidence. Health Policy 91:121–34
Grol R, Grimshaw J (2003) From best evidence to best practice: effective implementation of change in patients' care. Lancet 362(9391):1225–1230
Grol R, Wensing M (2004) What drives change? Barriers to and incentives for achieving evidence-based practice. Med J Aust 180[Suppl]:S57–S60
Wettermark B, Haglund K, Gustafsson LL, Persson PM, Bergman U (2005) A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists. Pharmacoepidemiol Drug Saf 14(8):579–588
Wisnivesky JP, Lorenzo J, Lyn-Cook R, Newman T, Aponte A, Kiefer E et al (2008) Barriers to adherence to asthma management guidelines among inner-city primary care providers. Ann Allergy Asthma Immunol 101(3):264–270
Cochrane GM, Horne R, Chanez P (1999) Compliance in asthma. Respir Med 93(11):763–769
Lindberg M, Ekstrom T, Moller M, Ahlner J (2001) Asthma care and factors affecting medication compliance: the patient's point of view. Int J Qual Health Care 13(5):375–383
Stallberg B, Nystrom Kronander U, Olsson P, Gottberg L, Ronmark E, Lundback B (2003) Living with asthma in Sweden–the ALMA study. Respir Med 97(7):835–843
Krigsman K, Melander A, Carlsten A, Ekedahl A, Nilsson JL (2007) Refill non-adherence to repeat prescriptions leads to treatment gaps or to high extra costs. Pharm World Sci 29(1):19–24
Acknowledgements
The authors are grateful to Andrejs Leimanis, EpC, The National Board of Health and Welfare, and Anders Hansson and Bengt Sjöborg, Department of Drug Management and Informatics, Stockholm County Council, for their invaluable contributions with the data extractions. We also acknowledge Brian Godman for valuable comments on this manuscript. The study was supported by the Centre for Allergy Research at Karolinska Institutet.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arnlind, M.H., Wettermark, B., Nokela, M. et al. Regional variation and adherence to guidelines for drug treatment of asthma. Eur J Clin Pharmacol 66, 187–198 (2010). https://doi.org/10.1007/s00228-009-0731-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-009-0731-7